ArticleFrontiers in endocrinology2022
The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension.
Abstract read
In one paragraph
Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Artificial Intelligence in Cardiovascular Medicine: Focus on Hypertension.Hypertension (Dallas, Tex. : 1979) · 2026Pooled it
- Efficacy and Safety of Aldosterone Synthase Inhibitors for Resistant Hypertension: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2025Pooled it
- A low dietary sodium dose is associated with a more pronounced aldosterone response in normotensive than in hypertensive individuals.Scientific reports · 2023Pooled it
- A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023Trial
- Dose-response efficacy and safety of the aldosterone synthase inhibitor baxdrostat in resistant hypertension: a systematic review and network meta-analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Zilebesiran, a Small Interfering RNA Therapeutic Targeting Angiotensinogen: Mechanism, Clinical Evidence, Safety, and Implementation Considerations.Life (Basel, Switzerland) · 2026Review
- Can baxdrostat redefine blood pressure control in resistant and uncontrolled hypertension? a systematic review, meta-analysis, and trial sequential analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Dose-Response Relationships and Comparative Efficacy of Aldosterone Synthase Inhibitors in Resistant Hypertension: A Comprehensive Network Meta-Analysis and Meta-Regression.Journal of clinical medicine · 2026Review
- Baxdrostat: A First-in-Class Aldosterone Synthase Inhibitor for Resistant Hypertension.ACS pharmacology & translational science · 2026Review
- Review
- Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial.Journal of the American Society of Nephrology : JASN · 2026Article
- Baxdrostat as a catalyst for precision hypertension: integrating pharmacogenomics, omics biomarkers, and digital phenotyping in resistant hypertension management.Clinical hypertension · 2026Article
- Baxdrostat: A Next-Generation Aldosterone Synthase Inhibitor Offering New Hope in Resistant Hypertension.Biomolecules · 2025Review
- Integrating Proteomics and Mendelian Randomization to Identify New Therapeutic Targets.American journal of hypertension · 2025Article
- Aldosterone: From Essential Tubular Regulator to Pathological Driver-Physiology, Disease, and Therapeutic Advances.International journal of molecular sciences · 2025Review
- Emerging therapeutic frontiers in hypertension management.Frontiers in cardiovascular medicine · 2025Review
- Discovery of RXFP2 genetic association in resistant hypertensive men and RXFP2 antagonists for the treatment of resistant hypertension.Scientific reports · 2024Article
- India Hypertension Control Initiative: Blood Pressure Control Using Drug and Dose-Specific Standard Treatment Protocol at Scale in Punjab and Maharashtra, India, 2022.Global heart · 2024Article
- Evaluating the role of aldosterone synthesis on adrenal cell fate.Frontiers in endocrinology · 2024Review
- Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA).Clinical kidney journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Imma ForzanoDDepartment of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Albert Einstein College of Medicine, New York, NY, United States.
Pasquale MoneDDepartment of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Albert Einstein College of Medicine, New York, NY, United States.
Fahimeh VarzidehDDepartment of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Albert Einstein College of Medicine, New York, NY, United States.
Stanislovas S JankauskasDDepartment of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Albert Einstein College of Medicine, New York, NY, United States.
Urna KansakarDDepartment of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Albert Einstein College of Medicine, New York, NY, United States.
Antonio De LucaDepartment of Mental and Physical Health and Preventive Medicine, Campania University "Luigi Vanvitelli", Caserta, Italy.
Gaetano SantulliDDepartment of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Albert Einstein College of Medicine, New York, NY, United States.
Funding
CTSA Administrative Supplement for Informatics Core: A novel AI/ML system to predict respiratory failure and ARDS in Covid-19 patientsUL1TR002556 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI KELLER, MARLA J, KIM, MIMI Y · 2018 to 2022
$26.7MREGULATION OF THE INSULIN RECEPTOR KINASER01DK033823 · NIDDK · UNIVERSITY OF IOWA · PI KURLAND, IRWIN JACK, PESSIN, JEFFREY E. · 1986 to 2022
$6.7MModulation of Mitofusin Activity to Treat Heart DiseaseR01HL159062 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI KITSIS, RICHARD N · 2021 to 2024
$2.6MCaspase-9 as a nodal point connecting necrotic and apoptotic cell death in myocardial infarctionR01HL164772 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI KITSIS, RICHARD N · 2022 to 2025
$2.5MFunctional role of IP3 receptors in the regulation of cardiac myofibroblastsR01HL146691 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SANTULLI, GAETANO · 2019 to 2023
$2.1MMechanisms of cardiovascular diseaseT32HL144456 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Carlos Jose Rodriguez, Nicholas E Sibinga · 2019 to 2026
$1.9MBeta Cell Intracellular Calcium and DiabetesR01DK123259 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SANTULLI, GAETANO · 2020 to 2023
$1.7MNCATS NIH HHS UL1 TR002556NHLBI NIH HHS R01 HL146691NHLBI NIH HHS R01 HL159062NHLBI NIH HHS R01 HL164772NHLBI NIH HHS T32 HL144456NIDDK NIH HHS R01 DK033823NIDDK NIH HHS R01 DK123259
Abstract
PubMed holds no abstract for this paper.
Indexed as
AldosteroneHypertensionBlood PressureCytochrome P-450 CYP11B2Enzyme InhibitorsHumansMineralocorticoid Receptor AntagonistsAldosteroneCytochrome P-450 CYP11B2Enzyme InhibitorsMineralocorticoid Receptor Antagonistsaldosteronebaxdrostatblood pressureBrigHTNCIN-107clinical trialhypertensionresistant hypertension
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.